Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in macaques

被引:62
作者
Polacino, PS
Stallard, V
Klaniecki, JE
Pennathur, S
Montefiori, DC
Langlois, AJ
Richardson, BA
Morton, WR
Benveniste, RE
Hu, SL
机构
[1] Univ Washington, Reg Primate Res Ctr, Seattle, WA 98121 USA
[2] Univ Washington, Dept Biostat, Seattle, WA 98121 USA
[3] Bristol Myers Squibb Pharmaceut Res Inst, Seattle, WA 98121 USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] NCI, Frederick, MD 21701 USA
关键词
D O I
10.1128/JVI.73.10.8201-8215.1999
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We previously showed that envelope (gp160)-based vaccines, used in a live recombinant virus priming and subunit protein boosting regimen, protected macaques against intravenous and intrarectal challenges with the homologous simian immunodeficiency virus SIVmne clone E11S. However, the breadth of protection appears to be limited, since the vaccines were only partially effective against intravenous challenge by the uncloned SIVmne. To examine factors that could affect the breadth and the efficacy of this immunization approach, we studied (i) the effect of priming by recombinant vaccinia virus; (ii) the role of surface antigen gp130; and (iii) the role of core antigens (Gag and Pol) in eliciting protective immunity. Results indicate that (i) priming with recombinant vaccinia virus was more effective than subunit antigen in eliciting protective responses; (ii) while both gp130 and gp160 elicited similar levels of SN-specific antibodies, gp130 was not as effective as gp160 in protection, indicating a possible role for the transmembrane protein in presenting functionally important epitopes; and (iii) although animals immunized with core antigens failed to generate any neutralizing antibody and were infected upon challenge, their virus load was 50- to 100-fold lower than that of the controls, suggesting the importance of cellular immunity or other core-specific immune responses in controlling acute infection. Complete protection against intravenous infection by the pathogenic uncloned SIVmne was achieved by immunization with both the envelope and the core antigens. These results indicate that immune responses to both antigens may contribute to protection and thus argue for the inclusion of multiple antigens in recombinant vaccine designs.
引用
收藏
页码:8201 / 8215
页数:15
相关论文
共 80 条
[41]   PROCESSING, ASSEMBLY, AND IMMUNOGENICITY OF HUMAN-IMMUNODEFICIENCY-VIRUS CORE ANTIGENS EXPRESSED BY RECOMBINANT VACCINIA VIRUS [J].
HU, SL ;
TRAVIS, BM ;
GARRIGUES, J ;
ZARLING, JM ;
SRIDHAR, P ;
DYKERS, T ;
EICHBERG, JW ;
ALPERS, C .
VIROLOGY, 1990, 179 (01) :321-329
[42]   IDENTIFICATION OF OVERLAPPING HLA CLASS I-RESTRICTED CYTOTOXIC T-CELL EPITOPES IN A CONSERVED REGION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEIN - DEFINITION OF MINIMUM EPITOPES AND ANALYSIS OF THE EFFECTS OF SEQUENCE VARIATION [J].
JOHNSON, RP ;
TROCHA, A ;
BUCHANAN, TM ;
WALKER, BD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (04) :961-971
[43]   T cell receptor usage and fine specificity of human immunodeficiency virus 1-specific cytotoxic T lymphocyte clones: Analysis of quasispecies recognition reveals a dominant response directed against a minor in vivo variant [J].
Kalams, SA ;
Johnson, RP ;
Dynan, MJ ;
Hartman, KE ;
Harrer, T ;
Harrer, E ;
Trocha, AK ;
Blattner, WA ;
Buchbinder, SP ;
Walker, BD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (04) :1669-1679
[44]   CROSS-NEUTRALIZING ANTIBODIES IN RABBITS IMMUNIZED WITH HIV-1 GP160 PURIFIED FROM SIMIAN CELLS INFECTED WITH A RECOMBINANT VACCINIA VIRUS [J].
KLANIECKI, J ;
DYKERS, T ;
TRAVIS, B ;
SCHMITT, R ;
WAIN, M ;
WATSON, A ;
SRIDHAR, P ;
MCCLURE, J ;
MOREIN, B ;
ULRICH, JT ;
HU, SL ;
LEWIS, J .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1991, 7 (10) :791-798
[45]   INVITRO ASSAYS FOR DETECTING NEUTRALIZING AND FUSION-INHIBITING ANTIBODIES TO SIVMAC251 [J].
LANGLOIS, AJ ;
WEINHOLD, KJ ;
MATTHEWS, TJ ;
BOLOGNESI, DP .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1991, 7 (08) :713-720
[46]   Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA pins protein vaccination [J].
Letvin, NL ;
Montefiori, DC ;
Yasutomi, Y ;
Perry, HC ;
Davies, ME ;
Lekutis, C ;
Alroy, M ;
Freed, DC ;
Lord, CI ;
Handt, LK ;
Liu, MA ;
Shiver, JW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (17) :9378-9383
[47]   Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization [J].
Lubeck, MD ;
Natuk, R ;
Myagkikh, M ;
Kalyan, N ;
Aldrich, K ;
Sinangil, F ;
Alipanah, S ;
Murthy, SCS ;
Chanda, PK ;
Nigida, SM ;
Markham, PD ;
ZollaPazner, S ;
Steimer, K ;
Wade, M ;
Reitz, MS ;
Arthur, LO ;
Mizutani, S ;
Davis, A ;
Hung, PP ;
Gallo, RC ;
Eichberg, J ;
RobertGuroff, M .
NATURE MEDICINE, 1997, 3 (06) :651-658
[48]   EVALUATION OF ANTIVIRAL DRUGS AND NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS BY A RAPID AND SENSITIVE MICROTITER INFECTION ASSAY [J].
MONTEFIORI, DC ;
ROBINSON, WE ;
SCHUFFMAN, SS ;
MITCHELL, WM .
JOURNAL OF CLINICAL MICROBIOLOGY, 1988, 26 (02) :231-235
[49]   Role of complement and Fc receptors in the pathogenesis of HIV-1 infection [J].
Montefiori, DC .
SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1997, 18 (03) :371-390
[50]   VACCINIA VIRUS - A TOOL FOR RESEARCH AND VACCINE DEVELOPMENT [J].
MOSS, B .
SCIENCE, 1991, 252 (5013) :1662-1667